Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.68
-20.4%
$5.05
$3.42
$7.20
$330.54M1.821.55 million shs6.29 million shs
BGM
BGM Group
$12.97
+2.5%
$12.25
$5.26
$17.17
$1.23B1.3831,259 shs115,790 shs
CureVac N.V. stock logo
CVAC
CureVac
$5.49
-0.2%
$3.92
$2.37
$5.72
$1.23B2.49804,970 shs1.01 million shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$14.41
+2.3%
$16.88
$6.80
$25.29
$1.25B0.751.62 million shs1.95 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-20.41%-22.52%-6.77%+2.41%-18.18%
BGM
BGM Group
+2.53%-20.67%+6.49%+45.08%+1,296,999,900.00%
CureVac N.V. stock logo
CVAC
CureVac
-0.18%+34.89%+41.86%+84.85%+68.92%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+2.27%-0.76%-15.29%-30.82%+102.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.1297 of 5 stars
0.02.00.00.00.00.80.6
BGM
BGM Group
N/AN/AN/AN/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
4.6169 of 5 stars
4.24.00.04.82.40.01.3
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.5458 of 5 stars
4.41.00.00.01.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
BGM
BGM Group
0.00
N/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
2.40
Hold$9.0063.93% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.14123.06% Upside

Current Analyst Ratings Breakdown

Latest ACB, BGM, TVTX, and CVAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $32.00
5/28/2025
CureVac N.V. stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/2/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/2/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$22.00 ➝ $23.00
4/30/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$200.35M1.31$0.18 per share26.31$8.18 per share0.57
BGM
BGM Group
$25.10M50.24N/AN/A$7.34 per share1.77
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.13$0.87 per share6.30$3.36 per share1.63
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M5.49N/AN/A$0.76 per share18.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0593.6210.64N/A0.42%0.59%0.42%6/18/2025 (Estimated)
BGM
BGM Group
-$1.44MN/A0.00N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.97N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)

Latest ACB, BGM, TVTX, and CVAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/1/2025Q1 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 million
4/10/2025Q4 2024
CureVac N.V. stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
BGM
BGM Group
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
BGM
BGM Group
N/A
3.39
2.82
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.46
2.05
2.03

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
BGM
BGM Group
N/A
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
BGM
BGM Group
58.66%
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,07356.21 million56.21 millionOptionable
BGM
BGM Group
29897.22 million40.19 millionN/A
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46088.81 million85.08 millionOptionable

Recent News About These Companies

Leerink Partnrs Has Pessimistic View of TVTX FY2025 Earnings
Travere Therapeutics, Inc. stock logo
What is HC Wainwright's Estimate for TVTX Q2 Earnings?
Leerink Partnrs Has Bearish Forecast for TVTX Q4 Earnings
Cantor Fitzgerald Comments on TVTX FY2026 Earnings
Travere Therapeutics, Inc. stock logo
Cantor Fitzgerald Predicts TVTX FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.68 -1.20 (-20.41%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$4.70 +0.02 (+0.32%)
As of 06/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

BGM Group NASDAQ:BGM

$12.97 +0.32 (+2.53%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$12.96 -0.01 (-0.04%)
As of 06/18/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.49 -0.01 (-0.18%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$5.48 -0.01 (-0.18%)
As of 06/18/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$14.41 +0.32 (+2.27%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$14.16 -0.26 (-1.77%)
As of 06/18/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.